Case Report
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 26, 2021; 9(6): 1329-1335
Published online Feb 26, 2021. doi: 10.12998/wjcc.v9.i6.1329
Efficacy of afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report
Shu-Yan He, Qing-Feng Lin, Jie Chen, Gui-Ping Yu, Jun-Ling Zhang, Dong Shen
Shu-Yan He, Qing-Feng Lin, Jie Chen, Dong Shen, Department of Medical Oncology, The Jiangyin Clinical College of Xuzhou Medical University, Jiangyin 214400, Jiangsu Province, China
Gui-Ping Yu, Department of Cardiothoracic Surgery, The Affiliated Jiangyin Hospital of Southeast University, Jiangyin 214400, Jiangsu Province, China
Jun-Ling Zhang, Medical Department, 3D Medicines Inc., Shanghai 201114, China
Author contributions: He SY and Shen D contributed to the study concept and design and performed the statistical analysis; Lin QF, Chen J, and Yu GP contributed to the acquisition, analysis, or interpretation of the data; Zhang JL contributed to the drafting of the manuscript; Zhang JL and Shen D contributed to the critical revision of the manuscript for important intellectual content.
Informed consent statement: Written informed consent was obtained from the patient for publication of this manuscript and any accompanying images.
Conflict-of-interest statement: Zhang JL is an employee of Shanghai 3D Medicines Inc. All other authors declare no competing interests.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Dong Shen, PhD, Chief Doctor, Professor, Department of Medical Oncology, The Jiangyin Clinical College of Xuzhou Medical University, No. 163 Shoushan Road, Jiangyin 214400, Jiangsu Province, China. sdshendong@126.com
Received: September 8, 2020
Peer-review started: September 8, 2020
First decision: November 20, 2020
Revised: December 3, 2020
Accepted: December 22, 2020
Article in press: December 22, 2020
Published online: February 26, 2021
Processing time: 150 Days and 18.3 Hours
Core Tip

Core Tip: EGFR represents the first identified targetable oncogenic driver discovered in non-small cell lung cancer (NSCLC). The most common EGFR mutations are in-frame deletions in exon 19 and point mutations in exon 21. However, rare mutations were found in nearly 10%-15% of EGFR-positive NSCLC and NSCLC with rare co-mutations had significantly different responses to EGFR tyrosine kinase inhibitor. Herein, we describe a rare case of rare EGFR G724S/R776H mutations and amplification in a NSCLC responding to afatinib.